№ lp_1_2_18410
File format: docx
Character count: 1925
File size: 24 KB
This document provides a table outlining the common, occasional, and rare side effects of Doxorubicin for use in cancer treatment, designed as a resource for clinical trial staff.
Year:
2025
Region / city:
US
Theme:
Cancer Treatment, Side Effects
Document Type:
Medical Resource
Organization:
National Cancer Institute (NCI)
Author:
Not specified
Target Audience:
Research Staff, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
November 13, 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document Type:
Supplementary material
Subject:
Drug synergy and population pharmacokinetic modeling
Drugs Studied:
Doxorubicin; Abemaciclib
Cell Lines:
MDA-MB-231; MDA-MB-468
Methods:
Western blot; HPLC; LC-MS/MS; Visual predictive check; Goodness-of-fit analysis
Data Type:
In vitro experimental data; Clinical pharmacokinetic data
Measurement Units:
µM; µg/mL; mg/m2; m2; hr
Sample Size:
n values ranging from 3 to 41
Referenced Publications:
1983–2018
Analytes:
Free doxorubicin; Pegylated liposomal doxorubicin; Total doxorubicin
Year:
2022
Type of document:
Medical Information
Target Audience:
Healthcare professionals and patients receiving ABVD chemotherapy
Subject:
Chemotherapy side effects
Date of approval:
March 17, 2022
Changes date:
N/A
Year:
2022
Region / City:
N/A
Topic:
Health / Medical
Document Type:
Informational
Author:
N/A
Target Audience:
Patients, Healthcare Professionals
Effective Period:
N/A
Approval Date:
N/A
Revision Date:
N/A
Description:
A list of possible side effects for the chemotherapy regimen EPOCH, including common, occasional, and rare side effects.
Document type:
Supplementary tables
Field of study:
Nanotechnology and cancer pharmacology
Test materials:
Yttrium-doped CuO-NPs; Silver-doped ZnO-NPs; Doxorubicin; Indomethacin; Zileuton; DMSO
Biological models:
Human colon cancer (CACO-2) cell line; Human lung cancer (A549) cell line; Human hepatocellular carcinoma (HEPG-2) cell line
Assays:
Cytotoxicity assay (Mean OD, Viability %, IC50); Enzymatic assay (Caspase-3, Bcl-2); In vitro anti-inflammatory assay (COX-1, COX-2, 5-LOX inhibition)
Sample size:
n = 3 per sample
Data presentation:
Mean ± SE
Measured units:
μg/mL; Pg/mL; ng/mL; %
Comparison standard:
Doxorubicin for cytotoxic and enzymatic assays; Indomethacin and Zileuton for anti-inflammatory assays
Experimental context:
In vitro evaluation of nanoparticle biological activity
Year:
2026
Region / city:
UK
Subject:
Electric Vehicle Charge Points, Heat Pumps, and connection procedures
Document Type:
Application form
Organization / institution:
Distribution Network Operators (DNOs)
Author:
Not specified
Target audience:
Individuals or entities installing electric vehicle charge points (EVCP) or heat pumps (HP)
Effective Period:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Year:
N/A
Region / City:
N/A
Theme:
Foster Care, Kinship Care, Child Welfare
Document Type:
Form
Agency / Institution:
N/A
Author:
N/A
Target Audience:
Agency Representatives, Foster Parents, Kinship Parents, Social Workers
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Contextual Description:
A form used for documenting and assessing the well-being and progress of children in various care placements, such as foster, therapeutic foster, or residential care.
Year:
2019
Region / city:
Geneva
Subject:
Madrid System for International Registration of Marks
Document type:
Working Group Report
Organization:
International Bureau
Author:
International Bureau
Target audience:
Member States and relevant stakeholders of the Madrid System
Period of validity:
Not specified
Date of approval:
May 21, 2019
Date of changes:
Not specified
Note:
Contextual description
Year:
2023
Region / City:
Forth Valley
Topic:
Incident Reporting, Controlled Drugs
Document Type:
Report Form
Organization / Institution:
NHS Forth Valley
Author:
Kirsty Peacock, Scott Mitchell
Target Audience:
NHS staff, Contractors
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not provided
Region / City:
Not provided
Theme:
Research methodology
Document type:
Academic paper
Organization:
AGH University of Science and Technology Press
Author:
Not specified
Target audience:
Researchers, academics, students
Period of validity:
Not specified
Approval date:
Not provided
Date of amendments:
Not provided
Year:
2024
Region / city:
USA
Topic:
Medical, Oncology
Document Type:
Educational Materials
Organization:
NCI CIRB
Author:
NCI
Target Audience:
Research staff, IRB members, clinical trial participants
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
United States
Topic:
Medicine, Side Effects, Clinical Trials
Document Type:
Educational Material
Organization:
NCI CIRB
Author:
N/A
Target Audience:
Research Staff, Clinical Trial Staff
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2024
Region / city:
USA
Topic:
Medical Information, Cancer Treatment
Document Type:
Educational Resource
Author:
National Cancer Institute (NCI)
Target Audience:
Research staff, Clinical trial participants, Healthcare professionals
Action Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2022
Region / City:
US
Topic:
Medical, Pharmacology
Document Type:
Research Resource
Organization / Institution:
National Cancer Institute (NCI)
Author:
Not specified
Target Audience:
Research staff, clinical trial personnel
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2024
Region / city:
USA
Theme:
Medical / Oncology
Document type:
Side Effect Table
Organization:
NCI CIRB
Target Audience:
Research staff, Clinical trial participants
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A
Year:
2023
Region / City:
United States
Topic:
Side effects of chemotherapy
Document type:
Educational Material
Organization / Institution:
National Cancer Institute (NCI)
Author:
Not specified
Target audience:
Research staff, clinical trial participants
Effective period:
Not specified
Approval date:
Not specified
Date of revisions:
Not specified
Year:
2025
Region / city:
United States
Topic:
Side effects of cancer therapy
Document type:
Patient Educational Material
Author:
National Cancer Institute
Target audience:
Research staff, clinical trial participants
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2023
Region / City:
United States
Topic:
Oncology, Pharmacology
Document Type:
Medical Information
Author:
NCI CIRB
Target Audience:
Clinical Research Staff
Period of Validity:
Indefinite
Approval Date:
Not Approved
Date of Changes:
March 22, 2023
Year:
2025
Region / City:
United States
Topic:
Medical, Side Effects of Drugs
Document Type:
Educational Material
Organization:
National Cancer Institute (NCI)
Author:
Not specified
Target Audience:
Research staff, Clinical trial participants
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Context